Skip to main content

To Our Valued Patients,

With the evolving situation of the Coronavirus (COVID-19) pandemic and under the guidelines of the Health Officer of the Alameda and Contra-Costa Counties, we will begin the process of re-opening our offices on Monday May 4th in order to provide needed eye and vision care. Moreover, cataract and all other non-cosmetic surgical procedures will soon resume.

Please keep in mind that in order to maintain social distancing protocols and to limit further transmission of the virus, we will be working with a reduced staff and seeing a fewer number of patients as compared to our “normal” schedule. Priority will be given to the most urgent medical cases. We will be implementing a number of measures (including altered check-in/check-out procedures, limiting the number of patients in the office and waiting room, face covering for all persons, temperature screening, etc) that will change your experience in the office. In addition, we will be ramping up our already strict disinfection policies and we will continue to monitor and abide by all local, state and, federal guidelines. Please bear with us through this new reality as these changes are designed to protect you and our staff.

We hope to see you soon and appreciate your trust in us to continue to meet your eye care needs. Stay safe and stay healthy!

The Turner Eye Institute Team

Menu

HELP KERATOCONUS

NORTHERN CALIFORNIA & SAN FRANCISCO BAY AREA SPECIALISTS

HELP KERATOCONUS

NORTHERN CALIFORNIA & SAN FRANCISCO
BAY AREA SPECIALISTS

Home » What's New » Crosslinking treatment of progressive keratoconus: new hope

Crosslinking treatment of progressive keratoconus: new hope

In the August 2006, Current Opinion in Ophthalmology, Gregory Wollensak presents his finding for the treatment of progressive keratoconus using collagen crosslinking by the photosensitzer riboflavin and ultraviolet A-light.  He summarizes that “biomechanical measurements have shown an impressive increase in corneal rigidity of 328.9% in human corneas after crosslinking.”

He further oncluded that, “The 3 and 5-year results of the Dresden clinical study have shown that in all treated 60 eyes the progression of keratoconus was at least stopped (‘freezing’). In 31 eyes there also was a slight reversal and flattening of the keratoconus by up to 2.87 diopters. Best corrected visual acuity improved slightly by 1.4 lines. So far, over 150 keratoconus patients have received crosslinking treatment in Dresden. Laboratory studies have revealed that the maximum effect of the treatment is in the anterior 300 μm of the cornea. As for the corneal endothelium, a cytotoxic level for endothelium was found to be 0.36 mW/cm2 which would be reached in human corneas with a stromal thickness of less than 400 μm.”

In summary, he stated that, “Collagen crosslinking by the photosensitzer riboflavin and ultraviolet A-light is an effective means for stabilizing the cornea in keratoconus. Collagen crosslinking might become the standard therapy for progressive keratoconus in the future diminishing significantly the need for corneal transplantation. Preoperative pachymetry and individual control of the ultraviolet A-irradiance before each treatment are mandatory. The treatment parameters must not be varied.”

Turner EYe Institute continues to maintain itself on the forefront of innovation.  For information regarding Keratoconus treatment, including collagen crosslinking, please contact our offices in San Jose, San Leandro, Concord, and San Francisco.